These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11585441)

  • 1. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3355-68. PubMed ID: 11585441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Ohashi N; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3369-77. PubMed ID: 11585442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 May; 49(5):606-12. PubMed ID: 11383615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bis-sulfonamides as endothelin receptor antagonists.
    Boss C; Bolli MH; Weller T; Fischli W; Clozel M
    Bioorg Med Chem Lett; 2003 Mar; 13(5):951-4. PubMed ID: 12617928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists.
    Kanda Y; Kawanishi Y; Oda K; Sakata T; Mihara SI; Asakura K; Kanemasa T; Ninomiya M; Fujimoto M; Konoike T
    Bioorg Med Chem; 2001 Apr; 9(4):897-907. PubMed ID: 11354672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
    Bolli MH; Boss C; Clozel M; Fischli W; Hess P; Weller T
    Bioorg Med Chem Lett; 2003 Mar; 13(5):955-9. PubMed ID: 12617929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
    Kanda Y; Takahashi T; Araki Y; Konoike T; Mihara S; Fujimoto M
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1875-8. PubMed ID: 10969989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
    Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC
    J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
    J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Sanagi M; Orita M; Nakahara H; Shimaya J; Tsukamoto S; Tanaka A; Yanagisawa I
    Bioorg Med Chem; 2001 Nov; 9(11):2955-68. PubMed ID: 11597477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
    Murugesan N; Tellew JE; Gu Z; Kunst BL; Fadnis L; Cornelius LA; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Panchal B; Valentine MT; Chong S; Morrison RA; Carlson KE; Powell JR; Moreland S; Barrish JC; Kowala MC; Macor JE
    J Med Chem; 2002 Aug; 45(18):3829-35. PubMed ID: 12190306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.
    Murugesan N; Gu Z; Stein PD; Spergel S; Bisaha S; Liu EC; Zhang R; Webb ML; Moreland S; Barrish JC
    Bioorg Med Chem Lett; 2002 Feb; 12(4):517-20. PubMed ID: 11844662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.
    Morimoto H; Shimadzu H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    Bioorg Med Chem Lett; 2002 Jan; 12(1):81-4. PubMed ID: 11738578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.
    Bradbury RH; Bath C; Butlin RJ; Dennis M; Heys C; Hunt SJ; James R; Mortlock AA; Sumner NF; Tang EK; Telford B; Whiting E; Wilson C
    J Med Chem; 1997 Mar; 40(6):996-1004. PubMed ID: 9083490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.
    Astles PC; Brown TJ; Halley F; Handscombe CM; Harris NV; Majid TN; McCarthy C; McLay IM; Morley A; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 2000 Mar; 43(5):900-10. PubMed ID: 10715156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of TA-0201, an endothelin receptor antagonist, with recombinant and human prostate endothelin receptors.
    Takahashi M; Taniguchi T; Tanaka T; Kanamaru H; Okada K; Muramatsu I
    Eur J Pharmacol; 2003 Apr; 467(1-3):185-9. PubMed ID: 12706473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tokunaga T; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 Dec; 49(12):1593-603. PubMed ID: 11767080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
    Stein PD; Floyd DM; Bisaha S; Dickey J; Girotra RN; Gougoutas JZ; Kozlowski M; Lee VG; Liu EC; Malley MF
    J Med Chem; 1995 Apr; 38(8):1344-54. PubMed ID: 7731020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced endothelin(A) receptor-mediated calcium mobilization and contraction in organ cultured porcine coronary arteries.
    Hill BJ; Katwa LC; Wamhoff BR; Sturek M
    J Pharmacol Exp Ther; 2000 Nov; 295(2):484-91. PubMed ID: 11046079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.